Other

Hong Kong IPO disclosure precedents · 8 companies, 8 items

2026-06-15Application Proof
Lynk Pharmaceuticals Co., Ltd.凌科药业(浙江)股份有限公司

During the Track Record Period, our redemption liabilities primarily represented preferred shares issued to investors with redemption rights.

Financial Information · p. 224

Our redemption liabilities decreased from RMB1,196.5 million as of December 31, 2024 to nil as of December 31, 2025, primarily due to the waiver of redemption rights by the holders of preferred shares in September 2025.

Financial Information · p. 224
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-19Application Proof
Suzhou Dongshan Precision Manufacturing Co., Ltd.苏州东山精密制造股份有限公司

Other gains/(losses), net of Source Photonics shifted from a loss of RMB50.2 million in 2023 to a gain of RMB634.8 million in 2024, primarily due to (i) an increase of RMB648.1 million in gain on modification of terms in Preferred Shares, (ii) a decrease of RMB49.1 million in fair value losses on financial liabilities at FVTPL, and (iii) an increase of RMB1.8 million in net foreign exchange gains, partially offset by a decrease of RMB10.3 million in net losses on disposal of property, plant and equipment and other long-term assets.

Financial Information · p. 232

The change was primarily due (i) a decrease of RMB648.1 million in gain on modification of terms in Preferred Shares, (ii) an increase of RMB41.6 million in compensation expense in connection with convertible bond and (iii) an increase of RMB58.0 million in fair value losses on financial liabilities at FVTPL, partially offset by a decrease of RMB1.9 million in net foreign exchange losses.

Financial Information · p. 229
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-14Application Proof
Guangdong Arcair Appliance Co., Ltd.广东合捷电器股份有限公司

We recorded redemption liabilities of approximately RMB22.5 million and RMB24.1 million as of 31 December 2023 and 2024, respectively.

Financial Information · p. 249

In August 2025, pursuant to a supplementary agreement signed between our [REDACTED] Investor and us, the investors’ redemption rights have been irrecoverably terminated and shall be void ab initio.

Financial Information · p. 249

Hence, as of 31 December 2025 and 31 March 2026, our redemption liabilities on ordinary shares amounted to nil and nil, respectively.

Financial Information · p. 249
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-04-07Application Proof
Wuhan Ammunition Life-tech Co., Ltd.武汉艾米森生命科技股份有限公司

Our redemption liabilities to financial investors decreased from RMB272.6 million as of December 31, 2024 to nil as of December 31, 2025 as the redemption liabilities were derecognized upon the termination of the special rights pursuant to a termination agreement dated May 8, 2025 and was reclassified to equity.

Financial Information · p. 242

Our redemption liabilities to financial investors are recognized as financial liabilities and are initially measured at fair value and subsequently measured at amortized cost.

Financial Information · p. 242
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-03-30Application Proof
Jiangsu Slender West Lake Culture and Tourism Co., Ltd.江苏瘦西湖文化旅游股份有限公司

We have redemption liability arising from a put option arrangements with non-controlling shareholders of Yangzhou Yuntong.

Financial Information · p. 221

The adjustments will be recognized as ‘‘Other expense’’ or ‘‘Other income and gains’’ in the statement of profit or loss and other comprehensive income. If the put option expires without delivery, the carrying amount of the liability is reclassified to equity.

Financial Information · p. 221
The company's explanation, the adviser's view and the page in the filing: see Matters
2025-12-15Prospectus
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.翰思艾泰生物医药科技(武汉)股份有限公司03378.HK

Our redemption liabilities increased from RMB101.5 million as of December 31, 2023 to RMB131.6 million as of December 31, 2024, which were primarily resulted from the redemption liabilities to Series B+ Investors.

Financial Information · p. 486

When the redemption rights related to the redeemable ordinary shares are terminated, the redemption liabilities on ordinary shares are extinguished and credited to equity.

Financial Information · p. 466
The company's explanation, the adviser's view and the page in the filing: see Matters
2024-12-12Prospectus
XIAOCAIYUAN INTERNATIONAL HOLDING LTD.小菜园国际控股有限公司00999.HK

(2) Changes in fair value of the convertible bonds and derivative financial instruments and changes in carrying amount of the redemption liability represent the change in the amount of the financial instruments issued to Harvest Delicacy in 2023 and 2024. Such change is non-cash in nature. Upon completion of the Global Offering, the financial instruments will be automatically converted into ordinary shares which will no longer be recognized as financial liabilities in the consolidated statements of financial position.

Summary · p. 19

We recorded other net losses of RMB2.2 million in the eight months ended August 31, 2023 and recorded other net income of RMB19.4 million in the eight months ended August 31, 2024, which was primarily due to a gain in changes in fair value of the convertible bonds and derivative financial instruments in the eight months ended August 31, 2024, partially offset by a loss in changes in carrying amount of the redemption liability in the eight months ended August 31, 2024, in relation to the financial instruments issued to Harvest Delicacy in 2023 and 2024.

Financial Information · p. 280
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-13Prospectus
WUHAN YZY BIOPHARMA CO., LTD.武汉友芝友生物制药股份有限公司02496.HK

From December 2020 to July 2021, we entered into a series of investment agreements with independent investors, namely the Series B Financing, Series B+ Financing and Series B++ Financing agreements, which we recognized as financial liabilities at amortized costs.

Financial Information · p. 490

However, our redemption liabilities on ordinary shares are non-cash items and have ceased to impact our financial performance since August 30, 2021, as we no longer recorded any redemption liabilities on ordinary shares since then, and our investors’ redemption rights were terminated on the same day.

Financial Information · p. 490

During the Track Record Period, we recognized the Series B, Series B+ and Series B++ preferred shares with redemption rights issued to investors as financial liabilities at amortized cost.

Financial Information · p. 517
The company's explanation, the adviser's view and the page in the filing: see Matters

Tell us